Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study
- 21 June 2018
- journal article
- research article
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 33 (12) , 1675-1683
Abstract
Peripheral sensory neuropathy is the most prominently reported adverse effect of oxaliplatin. The purpose of this study was to evaluate metformin role in oxaliplatin-induced neuropathy.Keywords
This publication has 43 references indexed in Scilit:
- The use of metformin is associated with decreased lumbar radiculopathy painJournal of Pain Research, 2013
- The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current StatusCurrent Colorectal Cancer Reports, 2013
- mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERKPain, 2013
- Resveratrol Engages AMPK to Attenuate ERK and mTOR Signaling in Sensory Neurons and Inhibits Incision-Induced Acute and Chronic PainMolecular Pain, 2012
- The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitusActa Diabetologica, 2011
- Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trialAnnals of Oncology, 2011
- Targeting Adenosine Monophosphate-Activated Protein Kinase (AMPK) in Preclinical Models Reveals a Potential Mechanism for the Treatment of Neuropathic PainMolecular Pain, 2011
- Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathwayBiochemical and Biophysical Research Communications, 2010
- Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendationsPain, 2010
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007